Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study, co-lead by Dr Felipe Galvez-Cancino from the Centre for Immuno-Oncology, has shown that Treg cell depletion can suppress tumour growth in one of the deadliest types of cancer.

A glioblastoma is a fast-growing type of brain tumour and the most common malignant brain tumour in adults. It’s considered to be one of the deadliest types of cancer as it responds poorly to immunotherapy.

Dr Felipe Galvez-Cancino, Kidani Fellow and Group Leader at NDM’s Centre for Immuno-Oncology, co-lead a study on the impact of regulatory T cell (Treg) depletion on the progression of glioblastoma and immunotherapy responsiveness.

The research found that Treg depletion suppressed tumour growth in preclinical models and in human tissues. In order to mediate Treg depletion, depleting antibodies are dependent on tumour-infiltrating macrophages that are specialised in antibody-dependent cellular phagocytosis. This means that after administering depleting antibodies to mice with glioblastomas, specific macrophages mediated the elimination of the target regulatory CD4+ T cells.

Ultimately, the data supported a negative role for Treg cells in glioblastoma and offers preclinical evidence that these cells could be eliminated with antibodies like anti-CD25. By identifying these mechanisms and gaining a better understanding of them, this research has uncovered a new therapeutic target for the treatment of glioblastoma, which opens the door to the development of novel therapies for this particular type of cancer.

If you’re interested in finding out more about this study, read the full paper on the Immunity Journal website:

 

Similar stories

New study confirms malaria drug safe for children and reduces disease burden

A major study in The Lancet Infectious Diseases confirms that single low-dose primaquine is safe and effective in reducing malaria transmission in young children. Analysing data from over 6,000 patients, researchers found it effective even in young children and areas with high malaria burden.